The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.

The patient derived xenograft (PDX) models market is experiencing rapid growth, driven by significant advancements in personalized medicine and cancer research. As we look toward the future, this market is expected to continue its upward trajectory, with a compound annual growth rate (CAGR) of 16% from 2023 to 2024. Here’s an overview of the key factors shaping this dynamic market.

Market Overview

• Current Market Size: Valued at $0.35 billion in 2023.
• Growth Projection: Expected to reach $0.4 billion by 2024.
• CAGR: 16% from 2023 to 2024.

Historical Growth Drivers

Several factors have contributed to the robust growth of the PDX models market:

• Research & Development Investments: Increased funding for innovative cancer research.
• Regulatory Support: Favorable regulations promoting PDX model usage.
• Partnerships and Collaborations: Enhanced research through strategic alliances.
• Rising Cancer Incidence: Growing number of cancer cases fueling research needs.
• Expansion of Contract Research Organizations (CROs): More CROs supporting PDX model research.

Future Growth Forecast

• Market Size by 2028: Projected to grow to $0.74 billion.
• Forecast CAGR: 16.1% from 2024 to 2028.

Read More On The Patient Derived Xenograft (PDX) Models Market Report 2024 –
https://www.thebusinessresearchcompany.com/report/patient-derived-xenograft-pdx-models-global-market-report

Key Growth Drivers for the Forecast Period:

• Demand for Personalized Medicine: Increasing need for tailored treatments.
• Humanized PDX Models: Rising interest in models that better replicate human diseases.
• Cancer Incidence: Growing cancer rates driving research.
• Precision Oncology: Focus on targeted cancer therapies.
• Increased R&D Investments: Boost in funding for cancer research initiatives.

Major Trends Influencing Growth

1. Technological Developments: Advances in PDX models and bioluminescence imaging.
2. Humanized PDX Models: Growing demand for more representative models.
3. Collaborative Research Initiatives: Increased joint research efforts.
4. Investment in Cancer Research: Rising funding for innovative cancer treatments.
5. Focus on Immuno-Oncology: Emphasis on developing new immunotherapy options.

Market Driver: Personalized Medicine

The demand for personalized medicine is a major driver for the PDX models market. Personalized medicine tailors treatment to individual genetic profiles, improving treatment efficacy. PDX models support this approach by:

• Testing Individual Tumors: Predicting patient-specific responses to treatments.
• Advancements in Genomics: Enabling more precise and personalized healthcare.

Example: The FDA approved 16 new personalized treatments for rare diseases in 2023, a significant increase from previous years, highlighting the growing focus on tailored therapies.

Key Market Players

Several major companies are leading the PDX models market, including:

• Laboratory Corporation of America Holdings
• WuXi AppTec Co. Ltd.
• Charles River Laboratories International Inc.
• The Jackson Laboratory
• Inotiv Inc

These players are actively developing innovative solutions to meet the rising demand for PDX models.

Trend: Advancements in PDX Models and Bioluminescence Imaging

Innovations in PDX models and bioluminescence imaging are enhancing research capabilities. In vivo bioluminescence imaging allows for:

• Real-Time Monitoring: Non-invasive tracking of tumor growth and treatment responses.
• Enhanced Preclinical Research: Improving drug development and targeted therapy evaluations.

Example: In March 2024, InVitro Research Solutions launched a model using bioluminescence imaging for glioblastoma research, improving the study of this aggressive brain cancer.

Recent Market Developments

• Merger and Acquisition: In November 2021, Inotiv Inc. acquired Envigo RMS Holding Corp. for $271 million, strengthening its research services and model offerings.

Market Segmentation

The PDX models market is segmented into:

1. Type: Mice Models, Rat Models
2. Technique: Heterotopic, Orthotropic Implantation
3. Tumor Type: Gastrointestinal, Lung, Hematological, Gynecological, Respiratory, Urological, Other
4. Application: Preclinical Drug Development, Precision Medicine, Co-Clinical Trials, Basic Cancer Research
5. End-User: Academic and Research Organizations, CROs, Pharmaceutical and Biotechnological Companies, Others

Regional Insights

• North America: The largest market in 2023.
• Asia-Pacific: Expected to be the fastest-growing region in the forecast period.

The patient derived xenograft (PDX) models market is set for continued growth, driven by technological advancements, increasing cancer research, and a shift towards personalized medicine. These trends will likely shape the future landscape of cancer research and treatment.

Request for A Sample Of The Global Patient Derived Xenograft (PDX) Models Market Report:
https://www.thebusinessresearchcompany.com/sample_request?id=17226&type=smp